Syntara Management

Management criteria checks 3/4

Syntara's CEO is Gary Phillips, appointed in Mar 2013, has a tenure of 11.67 years. total yearly compensation is A$830.67K, comprised of 56.7% salary and 43.3% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth €147.66K. The average tenure of the management team and the board of directors is 4.7 years and 4.7 years respectively.

Key information

Gary Phillips

Chief executive officer

AU$830.7k

Total compensation

CEO salary percentage	56.7%
CEO tenure	11.7yrs
CEO ownership	0.4%
Management average tenure	4.7yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gary Phillips's remuneration changed compared to Syntara's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$831k	AU$471k	-AU$14m
Mar 31 2024	n/a	n/a	-AU$10m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$18m
Jun 30 2023	AU$754k	AU$462k	-AU$13m
Mar 31 2023	n/a	n/a	AU$2m
Dec 31 2022	n/a	n/a	-AU$2m
Sep 30 2022	n/a	n/a	AU$2m
Jun 30 2022	AU$628k	AU$451k	-AU$2m
Mar 31 2022	n/a	n/a	-AU$16m
Dec 31 2021	n/a	n/a	-AU$12m
Sep 30 2021	n/a	n/a	-AU$1m
Jun 30 2021	AU$683k	AU$444k	-AU$3m
Mar 31 2021	n/a	n/a	AU$5m
Dec 31 2020	n/a	n/a	-AU$4m
Sep 30 2020	n/a	n/a	-AU$13m
Jun 30 2020	AU$559k	AU$440k	-AU$14m
Mar 31 2020	n/a	n/a	-AU$21m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$18m
Jun 30 2019	AU$613k	AU$433k	-AU$20m
Mar 31 2019	n/a	n/a	-AU$27m
Dec 31 2018	n/a	n/a	-AU$12m
Sep 30 2018	n/a	n/a	-AU$22m
Jun 30 2018	AU$776k	AU$424k	AU$6m

Compensation vs Market: Gary's total compensation ($USD536.78K) is about average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.

CEO

Gary Phillips (63 yo)

11.7yrs

Tenure

AU$830,674

Compensation

Mr. Gary Jonathan Phillips, BPharm, MBA, serves as Independent Non-Executive Director at Arovella Therapeutics Limited since July 1, 2022. He has been Chief Executive Officer and Managing Director of Synta...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gary Phillips	CEO, MD & Director	11.7yrs	AU$830.67k	0.42% € 147.7k
Wolfgang Jarolimek	Head of Drug Discovery	12.3yrs	AU$533.03k	0.13% € 44.6k
Kristen Morgan	Head of Medical & Regulatory Affairs - Alliance Management	no data	AU$360.60k	0.024% € 8.5k
Jana Baskar	Chief Medical Officer	2.3yrs	AU$455.75k	0.11% € 39.8k
David McGarvey	Company Secretary	less than a year	AU$603.03k	0.076% € 26.9k
Timothy Luscombe	Chief Financial Officer	less than a year	no data	no data
Cameron Billingsley	General Counsel	no data	no data	no data
Dieter Hamprecht	Head of Chemistry	7.1yrs	no data	no data

4.7yrs

Average Tenure

60yo

Average Age

Experienced Management: UUDA's management team is considered experienced (4.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gary Phillips	CEO, MD & Director	11.7yrs	AU$830.67k	0.42% € 147.7k
Simon Green	Independent Non-Executive Director	1.9yrs	AU$73.63k	0.066% € 23.6k
Kathleen M. Metters	Independent Non Executive Chair	7.4yrs	AU$112.80k	0.0015% € 519.4
Waradana Malitha De Silva	Non-Executive Director	1.8yrs	AU$73.63k	0.023% € 8.2k

4.7yrs

Average Tenure

Experienced Board: UUDA's board of directors are considered experienced (4.7 years average tenure).

Syntara Management

Management criteria checks 3/4

Key information

Recent management updates

Syntara Limited, Annual General Meeting, Nov 28, 2024

Syntara Limited Announces CFO Changes

Less than half of directors are independent

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Recent updates

Syntara Limited to Report Q1, 2025 Results on Oct 30, 2024

Syntara Limited, Annual General Meeting, Nov 28, 2024

New minor risk - Revenue size

Syntara Limited Announces CFO Changes

New major risk - Financial position

New minor risk - Financial position

New minor risk - Financial position

Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024

No longer forecast to breakeven

New major risk - Shareholder dilution

Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.

New major risk - Financial position

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

Less than half of directors are independent

Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings released: EPS: AU$0 (vs AU$0.003 loss in FY 2022)

Forecast to breakeven in 2026

New minor risk - Financial data availability

Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 Patients

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Pharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022

Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis Trial

Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring Study

Pharmaxis Ltd Updates on Phase 2 Study of the Pharmaxis Drug Discovery PXS4728

Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.007 loss in FY 2021)

Pharmaxis Ltd to Report Fiscal Year 2022 Final Results on Aug 23, 2022

Pharmaxis Ltd Announces Resignation of Will Delaat as Non Executive Director

Full year 2022 earnings released

Pharmaxis Limited Announces the Appointment of Dr. Jana Baskar as Chief Medical Officer

Pharmaxis Ltd, Annual General Meeting, Jul 11, 2022

Pharmaxis Ltd to Report Fiscal Year 2022 Results on Aug 11, 2022

Less than half of directors are independent

Second quarter 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd Announces First Patients Dosed in PXS Scar Reduction Trial

Independent Chairman of the Board recently bought €71k worth of stock

First quarter 2022 earnings released: AU$0.007 loss per share

Pharmaxis Ltd Announces Results of Data Analysis from the Second of Three Stages in Its Phase 1C Clinical Trial (MF-101) Studying Potential New Treatment for the Bone Marrow Cancer Myelofibrosis

Pharmaxis Announces Progression of Clinical Trial in Bone Marrow Cancer

Pharmaxis Ltd announced that it expects to receive AUD 4.366891 million in funding from Karst Peak Capital Limited, BVF Partners, L.P.

Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment

Pharmaxis Exports CF Drug to US

Second quarter 2021 earnings released

Revenue misses expectations

Pharmaxis Receives USD 7 Million Milestone from Chiesi

Pharmaxis Ltd, Annual General Meeting, Nov 03, 2021

Pharmaxis to Present at Proactive CEO Investor Session

First quarter earnings released

Pharmaxis Ltd Auditor Raises 'Going Concern' Doubt

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure